89
Participants
Start Date
December 31, 2008
Primary Completion Date
June 30, 2011
Study Completion Date
January 10, 2014
MORAb-009 (Amatuximab)
MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
Pemetrexed
Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Cisplatin
Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
Columbia University Medical Center, New York
HELIOS Klinikum Emil von Behring, Berlin
Christiana Care Health System, Newark
NIH/National Cancer Institute, Bethesda
Asklepios Klinik Harburg, Hamburg
Johns Hopkins University--Sidney Kimmel Comprehensive Cancer Center, Baltimore
Krankenhaus Großhansdorf, Großhansdorf
Mary Babb Randolph Cancer Center, Morgantown
Emory University School of Medicine, Atlanta
Medizinsche Hochschule Hannover, Hanover
Clínica Universitaria de Navarra, Pamplona
Fachklinik für Lungenerkrankungen Immenhausen, Immenhausen
University of Alabama, Birmingham, Birmingham
H. Virgen del Rocío, Seville
University of Chicago Medical Center, Chicago
University of Colorado Cancer Center, Aurora
Medizinische Klinik (Hämatologie/Onkologie), München
Asklepios Fachkliniken Müchen-Gauting, Gauting
UCLA Medical Hematology & Oncology, Los Angeles
University of California, San Diego, La Jolla
University of California, San Francisco, San Francisco
Princess Margaret Hospital, Toronto
Hopital Laval, Quebec, PQ
Medisch Spectrum Twente, Enschede
Erasmus MC, Rotterdam
H. de la Santa Creu i Sant Pau, Barcelona
Consorci Sanitari Parc Taulí, Barcelona
H. Son Dureta, Palma de Mallorca
Lead Sponsor
Morphotek
INDUSTRY